X-chromosomal mutations are a common cause of intellectual disability (X-linked intellectual disability \[XLID\]) in males accounting for 10%--12% of ID.^[@R1],[@R2]^ XLID is highly heterogeneous and is usually divided into syndromic and nonsyndromic forms, depending on the association with particular clinical findings.^[@R1],[@R2]^ Epileptic seizures accompany XLID in almost half the disorders, in some beginning in infancy prior to the developmental delay being evident. Recent next-generation sequencing (NGS) approaches have expedited the identification of XLID genes, including those associated with epilepsy,^[@R1][@R2][@R3]^ many of which encode proteins involved in synaptic function.^[@R4]^ *ARHGEF9* is one such gene,^[@R5][@R6][@R9]^ encoding collybistin (Cb), a brain-specific guanine nucleotide exchange factor with an essential role in inhibitory synaptic transmission.^[@R5]^ Cb interacts with the inhibitory receptor--anchoring protein gephyrin and is required for the formation of gephyrin and gephyrin-dependent GABA~A~ clusters in the postsynaptic membrane ([figure 1](#F1){ref-type="fig"}).^[@R5],[@R8],[@R10]^ Cb knockout mice exhibit increased anxiety, impaired spatial learning, and convulsions.^[@R10],[@R11]^

![Interaction of collybistin in the postsynaptic membrane\
Schematic representation of the interactions of collybistin in the formation of gephyrin and gephyrin-dependent GABA~A~ clusters in the postsynaptic membrane.](NG2016004051FF1){#F1}

Over 10 patients with *ARHGEF9* mutations have been reported,^[@R5][@R6][@R9],[@R12][@R13][@R15]^ indicating that this will likely be one of the more common XLIDs. Descriptions of the published cases vary from scant (in large NGS projects) to case reports with substantial detail. In the present study, we combine detailed descriptions of the phenotypes of 18 patients with *ARFGH9* mutations. In 4 cases, adequate detail was present at first published description. In 6 cases, we went back to the patients mentioned in tables of NGS results and worked with their physicians to obtain clinical details. The remaining are new unpublished patients.

METHODS {#s1}
=======

Two brothers (patients P10 and P11) with ID and epilepsy and unremarkable MRIs were tested by clinical whole-exome sequencing and found to have mutations in the *ARHGEF9* gene. Further 16 patients (including 5 females) with mutations or chromosomal disruptions affecting *ARHGEF9* were identified through a literature review and by contacting genetic centers in North America, Asia, and Europe.

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

A detailed developmental epilepsy and general medical history together with examination findings were obtained for each patient via a standardized questionnaire filled by their treating physician, or if this was not possible by a review of the described phenotypic features in publications. No samples were obtained from patients for research purposes. Written consent was obtained from patients\' parents for the publication of recognizable photographs.

X-chromosome inactivation analysis. {#s1-2}
-----------------------------------

In the unpublished cases (patients P1, P3, and P4) X-chromosome inactivation analysis was performed with the human androgen receptor assay: amplification of the CAG repeat in exon 1 of the androgen receptor gene was performed by PCR with fluorescence-tagged primers. Subsequently, digestion with the methylation-sensitive enzyme HpaII was performed, and fragments were analyzed with an automated capillary sequencer (ABI 3100; Applied Biosystems, Foster City, CA). Genescan and Genotyper Software (Applied Biosystems) were used to determine fragment sizes and intensities, and the degree of X-inactivation was calculated.

RESULTS {#s2}
=======

Genetic findings. {#s2-1}
-----------------

[Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} summarize the genetic findings of the 18 patients. Eleven had hemizygous *ARHGEF9* mutations, including premature stop codon, splicing, and point mutations. Six were de novo mutations; the 2 above brothers (P10 and 11) and patients P8, P15, and P18 showed a maternal inheritance, the latter with 3 affected brothers with a similar phenotype. Seven had chromosomal disruptions. The 11 mutations were in exons 8 (3), 9 (2), 1 (1), 3 (1), 4 (1), 5 (1), and 7 (1), and in intron 9 (1) (exon numbering based on the longest *ARHGEF9* transcript NM_015185.2). The patients with chromosomal disruptions had deletions (4), translocations (2), and a paracentric inversion (1). The 5 female patients all showed skewed X-inactivation of the normal chromosome.
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Genetic findings and phenotypic features of patients with *ARHGEF9* mutations or disruptions (females)
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Genetic findings and phenotypic features of patients with *ARHGEF9* mutations or disruptions (males)
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Clinical features. {#s2-2}
------------------

[Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} summarize the clinical features of the 18 patients.

### Demographics. {#s2-2-1}

Current age or age at last examination ranged from 4 to 57 years. Presenting symptoms: onset of symptoms occurred at a mean age of 15 months (median 9 months, range 1 day--7 years). Presenting symptoms varied from seizures (5), developmental delay in combination with seizures (4), and developmental delay/intellectual disability alone (6). One patient presented with hyperekplexia and seizures shortly after birth and 1 patient with hyperarousal and developmental delay (with no seizures).

### Intellectual disability. {#s2-2-2}

The majority of patients (13) showed delayed early developmental milestones. All patients had ID ranging from mild (1) to moderate (7) to severe (10). Of the 10 patients with severe ID, 7 were nonverbal.

### Neuropsychiatric features. {#s2-2-3}

Autistic features were reported in 4 patients. Five patients had hyperactivity.

### Dysmorphic features. {#s2-2-4}

Photographs for review of dysmorphic features were available for 9 of the 18 patients. Eight patients showed mild facial dysmorphic features. Out of this group, it appears that the male patients who are most severely affected with the overall neurologic syndrome (i.e., most severe ID and seizures) show more distinctive and consistent facial features, including enlarged, fleshy earlobes, a sunken appearance of the middle face (midface hypoplasia) in combination with a protruding of the jaw (prognathism) ([figure 2](#F2){ref-type="fig"}). Two patients showed 5-digit clinodactyly.

![Facial dysmorphism of 2 severely affected male patients\
Patients P6 (A) and P11 (B) from [tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Note enlarged fleshy earlobes, midface hypoplasia, and prognathism.](NG2016004051FF2){#F2}

### Neuroimaging findings. {#s2-2-5}

MRI data were available in 15 patients. Findings were none (7), hippocampal sclerosis (1), hypoplastic frontal lobe (1), brain atrophy (1), polymicrogyria (1), delayed myelination (1), or nonspecific (T2 hyperintensities, accentuated perivascular spaces) (3).

### Seizure/epilepsy details. {#s2-2-6}

Thirteen patients had epilepsy with onset at a mean age of 20 months (median 12 months, range 1 week--7 years). Seizure types were variable, including generalized tonic-clonic (9), focal dyscognitive (5), focal (4), myoclonic (1), and tonic (2) seizures. EEG findings were available for 11 of the 13 patients and showed generalized (3), bilateral (1), multifocal (1), and focal (1) epileptiform discharges and were normal in 2 patients. One patient with polymicrogyria showed continuous spike-and-wave discharges in slow-wave sleep. Two patients had only moderate background slowing.

### Epilepsy treatment. {#s2-2-7}

Four patients had medically refractory epilepsy, 4 showed 50% seizure reduction with antiepileptic drugs (AEDs), 1 showed seizure reduction of less than 50%, and 2 became completely seizure free without further AED treatment. AEDs consisted mainly of combination therapy (10); only 1 patient was on monotherapy (1).

Additional features included sleep disorder (4), ataxic gait (1), aggressive behavior (2), fetal finger and toe pads (2), pigmentation abnormalities (2), pectus excavatum (2), hyperreflexia (1), tachypnea (1), macro-orchidism (1), and insensitivity to thermal pain (1).

DISCUSSION {#s3}
==========

We describe and review the phenotypes of 18 patients with *ARHGEF9* mutations and chromosomal disruptions. Symptoms usually present in early childhood with delayed motor development alone or in combination with seizures. ID later on is usually moderate to severe with the majority of severe cases being nonverbal.

Epilepsy is common (13/18), starting usually at an early age (median 12 months). Seizure semiology is variable with a majority of patients showing generalized tonic-clonic seizures and many showing multiple seizure types. Most of the epilepsies were difficult to treat with 10 patients on combination AED therapy.

Facial dysmorphism, in particular, enlarged earlobes, midface hypoplasia, and prognathism appear to be a constant feature of the neurologically severely affected male patients.

The overall picture, therefore, is one of a moderate-to-severe XLID (with severe cases nonverbal), moderate-to-severe epilepsy (with severe cases poorly responsive or intractable to AEDs), and a facial dysmorphism in the severe cases.

Mothers of the various male patients in our study do not have XLID, indicating that random skewing of X-inactivation protects female carriers of *ARHGEF9* mutations. We did, however, find 5 female patients. X-inactivation studies in all 5 showed skewing in favor of the abnormal X-chromosome ([table 1](#T1){ref-type="table"}), rendering them equivalent to male counterparts with hemizygous mutations. The female phenotype would invariably be affected by remaining expression from the normal allele in cells in which it is active, and by differences in the extent of X-inactivation skewing in the brain compared to leucocytes.

Close analysis of males in the genotype and phenotype tables (1 and 2, respectively) suggests a tentative genotype---epilepsy phenotype correlation related to the region of the protein affected by the mutation. To clarify this, we briefly review some aspects of Cb structure and function. Inhibitory neurotransmitter receptor channels (GABA~A~ and glycine) imbedded in the postsynaptic membrane are anchored and clustered therein by a submembrane lattice composed of the gephyrin protein. The gephyrin lattice itself binds the plasma membrane via intermediary proteins critical among which is Cb. Cb binds gephyrin through its DH domain and attaches to the membrane through both its termini as follows: the N-terminal SH3 domain binds the membrane-integral neuroligin-2 protein, and the C-terminal PH domain binds the phosphoinositol 3-phosphate (PI~3~P) constituent of the plasma membrane ([figure 1](#F1){ref-type="fig"}).^[@R5],[@R8],[@R10]^ In male patients P6 and P7, the entire *ARHGEF9* gene is deleted, and in patient P8, there is a premature stop in the second codon ([table 1](#T1){ref-type="table"}). These 3 patients therefore lack Cb altogether, and their phenotypes would be representative of the complete loss of Cb function. [Table 2](#T2){ref-type="table"} shows that all 3 have severe ID and epilepsy. Patients 9 through 15 have various missense mutations affecting different regions of the protein, but not the C-terminal PI~3~P-interacting PH domain. All have epilepsy. Where functional experiments were performed (patients 9, 14, and 15), it was shown that the mutations result in loss of gephyrin clusters.^[@R5],[@R12],[@R16]^ The 3 remaining patients (16 through 18) all have mutations that affect the PH domain. None of these patients have epilepsy (and all have mild-to-moderate ID). Therefore, tentatively, mutations affecting only the PI~3~P-interacting C-terminus of the protein are not associated with epilepsy. Future functional experiments for these and subsequent PH domain mutations may uncover differences from the effects of the epileptogenic mutations and a possible understanding of epileptogenesis in this disease.

An additional important observation gleaned from our summary tables is comparing male patients P8 and P9 ([table 2](#T2){ref-type="table"}). Patient P8 has a stop mutation, p.Q2\*, in the very first exon, and his symptom constellation is very severe and similar to patients P6 and P7 in whom the entire gene is deleted. This first exon is coding, and therefore mutation p.Q2\* truncating, in a shorter transcript (NM_001173479) that skips over the next 2 exons utilized by the longest transcript (NM_015185.2) of the gene. The shorter transcript, NM_001173479, was confirmed to be highly expressed in both the developing and adult human brain and may be the dominant transcript.^[@R6]^ Patient P9 is the very first *ARHGEF9* patient described, and a striking feature of his presentation was hyperekplexia. His mutation is in exon 2, of the longer transcript, which is not utilized by the shorter transcript. Hyperekplexia is not found in any of the patients described after that first patient ([tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}), which suggests that this symptom may result from a particular function of the slightly longer protein encoded by the longer transcript.

As in so many other neurogenetic disorders, our review reveals that the *ARHGEF9* disease is not uniform and varies with the gene mutation and likely other genetic and extragenetic factors. Therefore, the diagnostic approach in candidate patients still requires chromosomal microarray testing as the first-line genetic testing because of the substantial diagnostic yield and low relative cost, followed by a gene panel or whole-exome sequencing approach as second tier.

There is, however, a core phenotype of moderate-to-severe ID and epilepsy with a facial dysmorphism (large earlobes, midface hypoplasia, and prognathism) in patients with complete loss of the gene\'s function.

This phenotype is moderated with lesser mutations---less severe intellectual disability and seizures, and absence of facial dysmorphism. As mentioned, mutations affecting the last exon alone appear to be nonepiletogenic.

[See editorial](http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000159)
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